Green Valley Pharma has ended its Phase III clinical trial for its Alzheimer’s drug due to funding issues and new COVID outbreaks in several major cities in China. Two years ago, the drugmaker won approval to market its Alzheimer’s drug in China. It hoped that its novel oral drug would gain approval, but the financial impact of the recent outbreaks and subsequent harsh lockdown measures proved too costly for the company.
According to Amber Tong of Endpoints News, “GV-971, the drug in question, is an oral capsule consisting of an oligosaccharide derived from seaweeds. While researchers had initially thought it may work by altering amyloid beta, Green Valley ultimately proposed that it works through the gut-brain axis, taming down nervous system inflammation through modulating gut microbiota.”
Read more by clicking here.
(Source: Endpoints News, May 16th, 2022)
